ABCG2 p.His630Glu
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 14566825
[PubMed]
Miwa M et al: "Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants."
No.
Sentence
Comment
6
Cells transfected with N557E-, H630E- or H630L-BCRP cDNA showed similar degrees of resistance to mitoxantrone and SN-38.
X
ABCG2 p.His630Glu 14566825:6:31
status: VERIFIED49 Among PA/ N557X3, PA/N557R expressed little BCRP. Among PA/H630X4 transfectants, moderate BCRP expression was observed in PA/ H630E.
X
ABCG2 p.His630Glu 14566825:49:126
status: VERIFIED58 PA/H630E and PA/H630L also showed similar degrees of resistance to mitoxantrone and SN-38 (Fig.
X
ABCG2 p.His630Glu 14566825:58:3
status: VERIFIED84 Estrone is the first physiological substrate that was shown to circumvents BCRP-mediated drug resistance.17 As shown in Table I, estrone effectively reversed mitoxantrone resistance and SN-38 resistance of PA/R482G, PA/R482S, PA/N557H, PA/N557D, PA/H630E and PA/H630L.
X
ABCG2 p.His630Glu 14566825:84:249
status: VERIFIED86 Similarly, fumitremorgin C, a well-known BCRP inhibitor, strongly reversed the mitoxantrone resistance and SN-38 resistance of PA/R482G, PA/R482S, PA/ N557H, PA/N557D, PA/H630E and PA/H630L (Table III).
X
ABCG2 p.His630Glu 14566825:86:171
status: VERIFIED106 PA/N557E, PA/H630E and PA/H630L showed similar degrees of resistance to mitoxantrone and SN-38.
X
ABCG2 p.His630Glu 14566825:106:13
status: VERIFIED140 TABLE I - REVERSAL OF MITOXANTRONE RESISTANCE AND SN-38 RESISTANCE BY ESTRONE1 Cell line Degree of Mitoxantrone resistance Reversal index Degree of SN-38 resistance Reversal index Control 10 M estrone Control 10 M estrone PA/WT1 7.1 Ϯ 0.6 2.2 Ϯ 0.4 3.2 28 Ϯ 1 4.7 Ϯ 0.3 6.0 PA/R482S 120 Ϯ 20 6.8 Ϯ 0.4 18 37 Ϯ 2 4.4 Ϯ 1.1 8.4 PA/R482G 84 Ϯ 17 3.7 Ϯ 0.3 23 22 Ϯ 1 3.3 Ϯ 0.1 6.7 PA/N557H 3.3 Ϯ 0.1 1.0 Ϯ 0.1 3.3 4.8 Ϯ 0.5 3.4 Ϯ 0.1 1.4 PA/N557D 7.4 Ϯ 0.2 1.4 Ϯ 0.1 5.3 3.8 Ϯ 0.6 2.9 Ϯ 0.2 1.3 PA/H630E 5.8 Ϯ 0.2 1.1 Ϯ 0.1 5.3 20 Ϯ 2.8 6.0 Ϯ 0.1 3.3 PA/H630L 3.3 Ϯ 0.1 0.9 Ϯ 0.1 3.7 8.6 Ϯ 0.4 2.7 Ϯ 0.1 3.2 1 Cells were cultured in the absence or presence of 10 M estrone with increasing concentrations of mitoxantrone or SN-38. Degree of resistance is the ratio of the IC50 value for BCRP-expressing cells divided by that for parental PA317.
X
ABCG2 p.His630Glu 14566825:140:630
status: VERIFIED143 The reversal index is calculated by dividing degree of resistance without estrone by that with estrone. TABLE III - REVERSAL OF MITOXANTRONE RESISTANCE AND SN-38 RESISTANCE BY FUMITREMORGIN C1 Cell line Degree of Mitoxantrone resistance Reversal index Degree of SN-38 resistance Reversal index Control 3 M Fumitremorgin C Control 3 M Fumitremorgin C PA/WT1 11 Ϯ 1 1.0 Ϯ 0.1 11 23 Ϯ 1 1.1 Ϯ 0.1 21 PA/R482S 140 Ϯ 10 1.2 Ϯ 0.1 120 41 Ϯ 1 0.9 Ϯ 0.1 46 PA/R482G 89 Ϯ 21 0.9 Ϯ 0.1 99 17 Ϯ 2 0.9 Ϯ 0.1 19 PA/N557H 3.3 Ϯ 0.1 1.0 Ϯ 0.1 3.3 4.8 Ϯ 0.5 1.1 Ϯ 0.1 4.4 PA/N557D 7.4 Ϯ 0.2 0.8 Ϯ 0.0 9.3 3.8 Ϯ 0.6 1.2 Ϯ 0.1 3.2 PA/H630E 5.8 Ϯ 0.2 1.1 Ϯ 0.1 5.3 20 Ϯ 2.8 1.4 Ϯ 0.1 14 PA/H630L 3.3 Ϯ 0.1 0.9 Ϯ 0.1 3.7 8.6 Ϯ 0.4 1.4 Ϯ 0.1 6.1 1 These cells were cultured in the absence or presence of 3 M fumitremorgin C with increasing concentrations of mitoxantrone or SN-38. Degree of resistance is the ratio of IC50 value for BCRP-expressing cells divided by that for parental PA317.
X
ABCG2 p.His630Glu 14566825:143:752
status: VERIFIED
PMID: 16108826
[PubMed]
Sugimoto Y et al: "Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics."
No.
Sentence
Comment
63
Cells transfected with N557E-BCRP, H630E-BCRP or H630L-BCRP cDNA showed similar degrees of resistance to mitoxantrone and SN-38.
X
ABCG2 p.His630Glu 16108826:63:35
status: VERIFIED
PMID: 16842198
[PubMed]
Perez-Tomas R et al: "Multidrug resistance: retrospect and prospects in anti-cancer drug treatment."
No.
Sentence
Comment
212
Cells transfected with N557E- or H630E or H630L-BCRP cDNA showed similar degrees of resistance to mitoxantrone and SN-38 than did wild-type BCRP-transfected cells.
X
ABCG2 p.His630Glu 16842198:212:33
status: VERIFIED
PMID: 17027309
[PubMed]
Li YF et al: "Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling study."
No.
Sentence
Comment
182
In sf9 cell, it is expressed on cell surface, but with no ATPase activity [56] L554P TM5 Lowered drug resistance [42] N557D,E TM5 Functional [21] S566Aa ECL (between TM5 and 6) Lowered drug resistance for the cell line [42] N596Q Between TM5 and 6 N-glycosylation site [65] Y605Ca Loop between TM5 and 6 Lowered drug resistance for the cell line [42] D620N Loop between TM5 and 6 SNP polymorphism [22] H630E,L TM6 Functional [21] A632Va TM Lowered drug resistance for the cell line [42] a Mutants not well characterized.
X
ABCG2 p.His630Glu 17027309:182:402
status: VERIFIED
PMID: 19111841
[PubMed]
Noguchi K et al: "Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy."
No.
Sentence
Comment
839
Cells expressing either the N557D or the H630E BCRP mutant displayed a lower resistance to SN-38, although the mitoxantrone-resistance of these cells was comparable to that observed for the wild-type BCRP-expressing cells.
X
ABCG2 p.His630Glu 19111841:839:41
status: VERIFIED